Optimal design methods that are robust to uncertainty
暂无分享,去创建一个
[1] Leon Aarons,et al. An Effective Approach for Obtaining Optimal Sampling Windows for Population Pharmacokinetic Experiments , 2008, Journal of biopharmaceutical statistics.
[2] C. Schermer,et al. Methamphetamine use in trauma patients: a population-based study. , 1999, Journal of the American College of Surgeons.
[3] Christopher J. Nachtsheim,et al. Model Robust, Linear-Optimal Designs , 1982 .
[4] James Miner,et al. Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam. , 2005, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[5] W K Wong,et al. Optimal treatment allocation in comparative biomedical studies. , 2000, Statistics in medicine.
[6] P Heizmann,et al. Pharmacokinetics and bioavailability of midazolam in man. , 1983, British journal of clinical pharmacology.
[7] S B Duffull,et al. Optimal Design Criteria for Discrimination and Estimation in Nonlinear Models , 2009, Journal of biopharmaceutical statistics.
[8] Donald Geman,et al. Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration of Images , 1984, IEEE Transactions on Pattern Analysis and Machine Intelligence.
[9] L. White. An extension of the General Equivalence Theorem to nonlinear models , 1973 .
[10] Vladimir Dragalin,et al. Implementation of an adaptive group sequential design in a bioequivalence study. , 2007, Pharmaceutical statistics.
[11] Stephen B. Duffull,et al. The use of simulated annealing for finding optimal population designs , 2002, Comput. Methods Programs Biomed..
[12] Stephen B. Duffull,et al. Optimal Design for Model Discrimination and Parameter Estimation for Itraconazole Population Pharmacokinetics in Cystic Fibrosis Patients , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[13] W. G. Hunter,et al. The use of prior distributions in the design of experiments for parameter estimation in non-linear situations: multiresponse case. , 1967, Biometrika.
[14] S. Duffull,et al. Estimating risk from underpowered, but statistically significant, studies: was APPROVe on TARGET? , 2011, Journal of clinical pharmacy and therapeutics.
[15] E. Läuter,et al. Optimal multipurpose designs for regression models , 1976 .
[16] P. Mykland,et al. Nonlinear Experiments: Optimal Design and Inference Based on Likelihood , 1993 .
[17] Stephen Duffull,et al. Methods of Robust Design of Nonlinear Models with an Application to Pharmacokinetics , 2010, Journal of biopharmaceutical statistics.
[18] K. Smith. ON THE STANDARD DEVIATIONS OF ADJUSTED AND INTERPOLATED VALUES OF AN OBSERVED POLYNOMIAL FUNCTION AND ITS CONSTANTS AND THE GUIDANCE THEY GIVE TOWARDS A PROPER CHOICE OF THE DISTRIBUTION OF OBSERVATIONS , 1918 .
[19] Shein-Chung Chow,et al. BRIDGING STUDIES IN CLINICAL DEVELOPMENT , 2002, Journal of biopharmaceutical statistics.
[20] Mats O. Karlsson,et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[21] Leon Aarons,et al. Bayesian Optimal Designs for Pharmacokinetic Models: Sensitivity to Uncertainty , 2007, Journal of biopharmaceutical statistics.
[22] Alain Mallet,et al. Optimal design in random-effects regression models , 1997 .
[23] M. Avram,et al. Dose‐Finding and Pharmacokinetic Study of Intramuscular Midazolam , 1987, Journal of clinical pharmacology.
[24] George E. P. Box,et al. SEQUENTIAL DESIGN OF EXPERIMENTS FOR NONLINEAR MODELS. , 1963 .
[25] J. Schumacher,et al. Chapter 27 – Anesthesia and Analgesia , 2006 .
[26] Anthony C. Atkinson,et al. DT-optimum designs for model discrimination and parameter estimation , 2008 .
[27] Martijn P. F. Berger,et al. OPTIMAL ALLOCATION OF TIME POINTS FOR THE RANDOM EFFECTS MODEL , 1999 .
[28] S L Shafer,et al. Comparative absorption kinetics of intramuscular midazolam and diazepam , 1996, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[29] P. Doelken,et al. Droperidol Causes a Dose‐dependent Prolongation of the QT Interval , 1994, Anesthesia and analgesia.
[30] M. Krams,et al. Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials , 2007, Journal of biopharmaceutical statistics.
[31] Peter B Chase,et al. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[32] J. W. A. S. Sander,et al. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy , 1991, Epilepsy Research.
[33] P. Laycock,et al. Optimum Experimental Designs , 1995 .
[34] Gordon Graham,et al. A program for the optimum design of pharmacokinetic, pharmacodynamic, drug metabolism and drug-drug interaction models , 2005, Comput. Methods Programs Biomed..
[35] France Mentré,et al. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..
[36] A. Atkinson,et al. The design of experiments for discriminating between two rival models , 1975 .
[37] M. J. Box. Simplified Experimental Design , 1971 .
[38] John Eccleston,et al. On optimal design for discrimination and estimation , 2004 .
[39] Sergei Leonov,et al. OPTIMAL POPULATION DESIGNS FOR PK MODELS WITH SERIAL SAMPLING , 2004, Journal of biopharmaceutical statistics.
[40] H. Chernoff. Locally Optimal Designs for Estimating Parameters , 1953 .
[41] France Mentré,et al. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0 , 2010, Comput. Methods Programs Biomed..
[42] S B Duffull,et al. Optimal Crossover Designs for Logistic Regression Models in Pharmacodynamics , 2006, Journal of biopharmaceutical statistics.
[43] M Tod,et al. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. , 1996, Computer methods and programs in biomedicine.
[44] D. Cox,et al. Planning Experiments for Discriminating between Models , 1974 .
[45] William A. Cressman,et al. Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. , 1973, Anesthesiology.
[46] W A Cressman,et al. Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. , 1973, Anesthesiology.
[47] Barbara Bogacka,et al. D-efficient window experimental designs , 2008 .
[48] H. Cramér. Mathematical methods of statistics , 1947 .
[49] Malcolm Rowland,et al. Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[50] Jean-Marie Rocchisani,et al. Comparison of ED, EID, and API Criteria for the Robust Optimization of Sampling Times in Pharmacokinetics , 1997, Journal of Pharmacokinetics and Biopharmaceutics.
[51] L B Sheiner,et al. Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.
[52] Anthony C. Atkinson,et al. Optimum Experimental Designs , 1992 .
[53] W. G. Hunter,et al. Design of experiments for parameter estimation in multiresponse situations , 1966 .
[54] F. Hsuan,et al. Adaptive Designs for Dose-Finding Studies Based on Sigmoid E max Model , 2007, Journal of biopharmaceutical statistics.
[55] Stephen B Duffull,et al. Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. , 2008, British journal of clinical pharmacology.
[56] Donald Geman,et al. Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images , 1984 .
[57] M. Kirk,et al. Droperidol, QT prolongation, and sudden death: what is the evidence? , 2003, Annals of emergency medicine.
[58] N. Votolato,et al. The use of intramuscular benzodiazepines and antipsychotic agents in the treatment of acute agitation or violence in the emergency department. , 2006, The Journal of emergency medicine.
[59] J. Kiefer,et al. The Equivalence of Two Extremum Problems , 1960, Canadian Journal of Mathematics.
[60] P. Hartvig,et al. Pharmacokinetics of midazolam in total i.v. anaesthesia. , 1987, British journal of anaesthesia.
[61] Stephen B. Duffull,et al. Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[62] Jon Wakefield,et al. Bayesian individualization via sampling-based methods , 1996, Journal of Pharmacokinetics and Biopharmaceutics.
[63] Stephen B Duffull,et al. The time course of drug effects , 2009, Pharmaceutical statistics.
[64] L. Endrenyi. Design of Experiments for Estimating Enzyme and Pharmacokinetic Parameters , 1981 .
[65] Andrew C. Hooker,et al. Robust Population Pharmacokinetic Experiment Design , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[66] Ian Whyte,et al. Safety and effectiveness of high‐dose midazolam for severe behavioural disturbance in an emergency department with suspected psychostimulant‐affected patients , 2008, Emergency medicine Australasia : EMA.
[67] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[68] L C Ward,et al. Optimal designs for studying bioimpedance , 2007, Physiological measurement.
[69] Doug Sellman,et al. Alcohol and drug treatment population profile: a comparison of 1998 and 2004 data in New Zealand. , 2006, The New Zealand medical journal.
[70] Leon Aarons,et al. Optimisation of sampling windows design for population pharmacokinetic experiments , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[71] E. Walter,et al. Robust experiment design via maximin optimization , 1988 .
[72] Leon Aarons,et al. Analytical Expressions for Combining Population Pharmacokinetic Parameters from Different Studies , 2008, Journal of biopharmaceutical statistics.
[73] C. R. Rao,et al. Information and the Accuracy Attainable in the Estimation of Statistical Parameters , 1992 .
[74] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[75] G. W. Morgan,et al. Kinetic Data Analysis, Design and Analysis of Enzyme and Pharmacokinetic Experiments , 1981 .
[76] G. Elfving. Optimum Allocation in Linear Regression Theory , 1952 .
[77] W. G. Hunter,et al. The use of prior distributions in the design of experiments for parameter estimation in non-linear situations. , 1967, Biometrika.
[78] John Battaglia,et al. Pharmacological Management of Acute Agitation , 2012, Drugs.
[79] L Pronzato,et al. Optimal experiment design for nonlinear models subject to large prior uncertainties. , 1987, The American journal of physiology.
[80] A. Wald. On the Efficient Design of Statistical Investigations , 1943 .
[81] W. G. Cochran. Experiments for Nonlinear Functions (R.A. Fisher Memorial Lecture) , 1973 .
[82] W. J. Studden,et al. Theory Of Optimal Experiments , 1972 .
[83] William L. Goffe,et al. SIMANN: FORTRAN module to perform Global Optimization of Statistical Functions with Simulated Annealing , 1992 .
[84] Leon Aarons,et al. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments , 2006, Statistics in medicine.
[85] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic data , 1983, Journal of Pharmacokinetics and Biopharmaceutics.
[86] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.
[87] D. Taylor,et al. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. , 2006, Annals of emergency medicine.
[88] M. Leider. Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .
[89] M. J. Eadie,et al. The pharmacokinetics of midazolam in man , 2004, European Journal of Clinical Pharmacology.
[90] Alan Maloney,et al. An example of optimal phase II design for exposure response modelling , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[91] John H Shale,et al. A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. , 2003, The Journal of clinical psychiatry.
[92] France Mentré,et al. Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.
[93] P. Zed,et al. Drug-Related Visits to the Emergency Department , 2005 .
[94] France Mentré,et al. Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics , 2009 .
[95] David Z. D'Argenio,et al. Optimal sampling times for pharmacokinetic experiments , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[96] M. J. Box. Some Experiences with a Nonlinear Experimental Design Criterion , 1970 .
[97] M. J. Box. The Occurrence of Replications in Optimal Designs of Experiments to Estimate Parameters in Non‐Linear Models , 1968 .
[98] Mats O Karlsson,et al. Optimal Adaptive Design in Clinical Drug Development: A Simulation Example , 2007, Journal of clinical pharmacology.
[99] I. Patel,et al. Effects of Age, Gender and Oral Contraceptives on Intramuscular Midazolam Pharmacokinetics , 1988, Journal of clinical pharmacology.
[100] A. Atkinson,et al. Optimal design : Experiments for discriminating between several models , 1975 .
[101] D Z D'Argenio,et al. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.
[102] Shane Darke,et al. Non-fatal cocaine overdose among injecting and non-injecting cocaine users in Sydney, Australia. , 2004, Addiction.
[103] J. Kiefer,et al. Optimum Designs in Regression Problems , 1959 .
[104] H. L. Lucas,et al. DESIGN OF EXPERIMENTS IN NON-LINEAR SITUATIONS , 1959 .
[105] W. G. Cochran. Experiments for Nonlinear Functions , 1973 .
[106] J. I. The Design of Experiments , 1936, Nature.
[107] Weng Kee Wong,et al. On the Equivalence of Constrained and Compound Optimal Designs , 1994 .